Retrospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Dec 14, 2015; 21(46): 13101-13112
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13101
Table 6 Univariate and multivariate analysis for overall survival
Prognostic factorsUnivariate analysis
Multivariate analysis
Hazard ratio95%CIP valueHazard ratio95%CIP value
Gender (male)0.9680.387-2.4190.945
Age (≥ 70 yr)0.7700.355-1.6700.508
AFP (≥ 400 ng/mL)2.6621.181-6.0010.0182.5481.070-6.0680.035
BCLC (terminal)7.0222.442-20.19< 0.0019.8092.589-37.17< 0.001
Child-Pugh (≥ 7)3.0311.258-7.3010.0131.3640.510-3.6450.536
Diameter (≥ 30 mm)0.6540.285-1.5000.316
Dose (≥ 30 Gy)0.3020.114-0.8040.0170.2740.093-0.75410.012
Dose/fraction (≥ 8 Gy)1.8890.790-4.5160.153
Lesion (extrahepatic)1.7890.665-4.8170.250
Fiducial (+)0.4910.195-1.2380.1320.7830.264-2.3210.659
Sorafenib (+)1.0680.247-4.6180.930